Scarica l'app Stockscreener
3.56
2,185%
3.4042
Dopo l'orario di chiusura:
3.46
-0.10
-2.81%
Precedente Chiudi:
$0.1558
Aprire:
$3.75
Volume 24 ore:
586.92K
Relative Volume:
0.06
Capitalizzazione di mercato:
$24.43M
Reddito:
$5.21M
Utile/perdita netta:
$-26.35M
Rapporto P/E:
-0.111
EPS:
-32.0862
Flusso di cassa netto:
$-20.84M
1 W Prestazione:
+1,366%
1M Prestazione:
+1,088%
6M Prestazione:
+421.61%
1 anno Prestazione:
+299.91%
Intervallo 1D:
$3.30
$3.81
Intervallo di 1 settimana:
$0.129
$3.81
Portata 52W:
$0.129
$3.81
Plus Therapeutics Inc Stock (PSTV) Company Profile
Nome
Plus Therapeutics Inc
Settore
Industria
Telefono
737.255.7194
Indirizzo
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
3.56 | 24.43M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-03 | Iniziato | Lake Street | Buy |
| 2025-09-03 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Iniziato | D. Boral Capital | Buy |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-16 | Iniziato | Maxim Group | Buy |
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Volume Report: Is Plus Therapeutics Inc a top pick in the sectorTrade Exit Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Plus Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | XMP1 | US72941H8060 - marketscreener.com
Plus Therapeutics Inc (XMP0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Plus Therapeutics: Financial Data Forecasts Estimates and Expectations | XMP0 | US72941H8060 - marketscreener.com
Plus Therapeutics: Target Price Consensus and Analysts Recommendations | XMP0 | US72941H8060 - marketscreener.com
Plus Therapeutics Inc (FRA:XMP1) Stock Earnings Transcripts - GuruFocus
Tranche Update on Plus Therapeutics, Inc.'s Equity Buyback Plan announced on October 31, 2023. - marketscreener.com
Plus Therapeutics: Revenue and Earnings Analysts Forecasts Revisions | XMP0 | US72941H8060 - MarketScreener
Plus Therapeutics Inc Stock Operating Data - GuruFocus
Plus Therapeutics Inc (FRA:XMP1) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Plus Therapeutics Inc (FRA:XMP1) Stock Price & 30 Year Financial Data - GuruFocus
Plus Therapeutics Inc (FRA:XMP1) Stock News, Headlines & Updates - GuruFocus
Plus Therapeutics Inc (FRA:XMP1) Stock Price, Trades & News - GuruFocus
Plus Therapeutics: Dividend historical data and projections - marketscreener.com
Plus Therapeutics Enacts Reverse Stock Split to Maintain Listing - TipRanks
Reverse split shrinks Plus Therapeutics (NASDAQ: PSTV) share count to 6.9M - Stock Titan
Plus Therapeutics (NASDAQ:PSTV) Stock Price Down 9.9%Here's Why - MarketBeat
Plus Therapeutics Expands Reimbursement for CNSide® CSF Assay to 75 Million Covered Lives - National Today
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives - manilatimes.net
PSTV Stock Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sims Andrew John Hugh MacIntyremoomoo - Moomoo
Plus Therapeutics (PSTV) CFO acquires 67,452 shares through RSU vesting - Stock Titan
Plus Therapeutics (PSTV) CEO exercises 361,313 RSUs into stock - Stock Titan
Plus Therapeutics Inc. (NASDAQ:PSTV) - intelligentinvestor.com.au
Plus Therapeutics approves 1-for-25 reverse stock split By Investing.com - Investing.com Australia
Plus Therapeutics, Inc. Announces 1-for-25 Reverse Stock Split Effective April 2, 2026 - Moomoo
Plus Therapeutics | DEF 14A: Definitive information statements - moomoo.com
Published on: 2026-04-01 11:00:22 - baoquankhu1.vn
Plus Therapeutics To Carry Out 1-for-25 Reverse Stock Split On April 2nd, 2026 - Moomoo
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Plus Therapeutics Approves 1-for-25 Reverse Stock Split - Intellectia AI
[ARS] PLUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Plus Therapeutics (NASDAQ: PSTV) sets 2026 virtual meeting, executive pay and equity plan vote - Stock Titan
Plus Therapeutics announces 1-for-25 reverse stock split - MSN
This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdayCentessa P - Benzinga
Plus Therapeutics (PSTV) Downgraded to Hold by D. Boral Capital - GuruFocus
Plus Therapeutics Announces Reverse Stock Split - Bitget
D. Boral Capital downgrades Plus Therapeutics stock rating on reverse split By Investing.com - Investing.com South Africa
D. Boral Capital downgrades Plus Therapeutics stock rating on reverse split - Investing.com
Plus Therapeutics approves 1-for-25 reverse stock split - Investing.com
Plus Therapeutics announces reverse stock split - MarketScreener
PLUS THERAPEUTICS (PSTV) director files Form 3 with zero shares - Stock Titan
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
PLUS THERAPEUTICS, INC. Files Form 8-K Current Report with SEC – Company Details, Address, and Compliance Information 18 - Minichart
Plus Therapeutics Appoints Ron Andrews to Board - Intellectia AI
Plus Therapeutics appoints Ronald A. Andrews to board following director resignation By Investing.com - Investing.com South Africa
Plus Therapeutics Adds Industry Veteran Ronald Andrews to Board - TipRanks
Plus Therapeutics appoints Ronald A. Andrews to board following director resignation - Investing.com
Plus appoints Ronald A. Andrews to Board as Robert Lenk resigns - TradingView
Ronald Andrews joins Plus Therapeutics (NASDAQ: PSTV) board - Stock Titan
Plus Therapeutics appoints Ron Andrews to board of directors By Investing.com - Investing.com India
Plus Therapeutics Inc Azioni (PSTV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Plus Therapeutics Inc Azioni (PSTV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HEDRICK MARC H | Chief Executive Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
499,468 |
| HEDRICK MARC H | Chief Executive Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
339,787 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
38,323 |
0 |
106,461 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Nov 04 '25 |
Buy |
0.51 |
20,000 |
10,200 |
68,138 |
| HEDRICK MARC H | Chief Executive Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
159,681 |
0 |
180,106 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
38,323 |
0 |
48,138 |
| Lenk Robert P | Director |
Aug 22 '25 |
Buy |
0.49 |
110,000 |
53,779 |
139,327 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):